Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office
February 15, 2024 18:35 ET
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 16 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), today announces that at a meeting held on 15 February 2024, its Board of...
Monthly information on share capital and company voting rights
February 02, 2024 16:30 ET
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers
February 01, 2024 07:00 ET
|
Societal CDMO, Inc.
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing...
Orange Grove Bio Sets Sights on Rapidly Emerging Middle East Biotech Ecosystem through New Academic Collaboration with Weizmann Institute of Science
January 31, 2024 07:00 ET
|
Orange Grove Bio
CINCINNATI, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orange Grove Bio, a drug investment and development firm, today announced that it has established a new strategic collaboration with Bina, the...
First Wave BioPharma to Present at the DealFlow MicroCap Conference
January 23, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico
January 17, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
January 16, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Single Use Support continues to grow, expanding its team by 40%
January 16, 2024 07:45 ET
|
Single Use Support
The forecast for innovative process solution provider Single Use Support promises growth, exemplified by the addition of 40% more staff members.
Monthly information on share capital and company voting rights
January 08, 2024 16:30 ET
|
Cellectis Inc.
PARIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
January 04, 2024 06:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...